Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$70.00K$70.00Kno prior Q3 2022 on file Net Income$115.31K$115.31KN/M vs Q3 2022 EPS Diluted$0.00$0.00— vs Q3 2022 Operating Income$14,478N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin20.7%
Net margin164.7%
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end